Advertisement
Advertisement

DMAA

D

Drugs Made In America Acquisition Corp. Ordinary Shares

10.41
USD
Sponsored
0.00
+0.01%
Jan 20, 12:32 UTC -5
Open

DMAA Earnings Reports

Positive Surprise Ratio

No Data Available for DMAA

0%

Next Report

Date of Next Report
Mar 18, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

Drugs Made In America Acquisition Corp. Ordinary Shares earnings per share and revenue

On Nov 17, 2025, DMAA reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
WaFd, Inc. Depositary Shares
Report Date
Jan 15, 2026 For Q1 26
Estimate
$0.76
Actual
$0.79
Surprise
+2.85%
FAQ
For Q3 2025, Drugs Made In America Acquisition Corp. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for Mar 18, 2026.
Based on -- analysts, Drugs Made In America Acquisition Corp. Ordinary Shares is expected to report EPS of -- and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement